| Collin Flanders, | |
|
2121 N 1700 W, Layton, UT 84041-8803 | |
| (801) 773-4840 | |
| (801) 525-8151 |
| Full Name | Collin Flanders |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 2121 N 1700 W, Layton, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356922793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | (* (Not Available)) | Primary |
| Entity Name | Tanner Memorial Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447239355 PECOS PAC ID: 4284547985 Enrollment ID: O20031110000132 |
News Archive
Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.
The University of California, Davis Department of Chemistry will spotlight a special focus on rare disease research with this year's 15th annual R. Bryan Miller Symposium. Experts in rare diseases will gather at the UC Davis Conference Center March 5 for a conference highlighting the opportunities and challenges in applying cutting edge technologies and "precision medicine" to better treat conditions that together affect millions of people, especially children.
Scientists have discovered a new genetic disease, which causes some children's brains to develop abnormally, resulting in delayed intellectual development and often early onset cataracts.
The University of Michigan School of Dentistry and Interleukin Genetics, Inc. announced today the completion of patient enrollment for a landmark clinical study using Interleukin's PST Genetic Test to determine if dental patients can be risk-stratified to guide frequency of preventive dental visits and reduce the adverse outcomes of periodontal disease progression, such as tooth loss.
Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Collin Flanders, Po Box 337, Layton, UT 84041-0337 Ph: (801) 773-4840 | Collin Flanders, 2121 N 1700 W, Layton, UT 84041-8803 Ph: (801) 773-4840 |
News Archive
Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.
The University of California, Davis Department of Chemistry will spotlight a special focus on rare disease research with this year's 15th annual R. Bryan Miller Symposium. Experts in rare diseases will gather at the UC Davis Conference Center March 5 for a conference highlighting the opportunities and challenges in applying cutting edge technologies and "precision medicine" to better treat conditions that together affect millions of people, especially children.
Scientists have discovered a new genetic disease, which causes some children's brains to develop abnormally, resulting in delayed intellectual development and often early onset cataracts.
The University of Michigan School of Dentistry and Interleukin Genetics, Inc. announced today the completion of patient enrollment for a landmark clinical study using Interleukin's PST Genetic Test to determine if dental patients can be risk-stratified to guide frequency of preventive dental visits and reduce the adverse outcomes of periodontal disease progression, such as tooth loss.
Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania.
› Verified 4 days ago
Ms. Marilyn D Stephens-burton, LMFT, M.A Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 930 W Hill Field Road, Suite A, Layton, UT 84041 Phone: 801-336-3040 Fax: 801-336-3041 | |
Brian Reeves, LAMFT Couples Therapy Medicare: Medicare Enrolled Practice Location: 934 S Main St, Layton, UT 84041 Phone: 801-336-1845 | |
Matthew Lefthand, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1730 E 3100 N Ste 2, Layton, UT 84040 Phone: 801-458-0665 | |
Nefily Ledezma, LMFT Couples Therapy Medicare: Medicare Enrolled Practice Location: 934 S Main St, Layton, UT 84041 Phone: 801-773-7060 Fax: 801-336-1787 | |
Daniel Stuart, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 930 W Hill Field Rd, Layton, UT 84041 Phone: 801-913-8790 | |
Amanda Van Leeuwen Jenks, MFT INTERN Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1660 W Antelope Dr Ste 301, Layton, UT 84041 Phone: 435-213-9278 | |
Alexis Anne Lee, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1650 W Gentile St, Layton, UT 84041 Phone: 801-485-8051 |